Evidence map›Paper›PMID 28199987›Full record

ArticleOncotarget2017

MiR-34a promotes DCs development and inhibits their function on T cell activation by targeting WNT1.

Anfei Huang, Yi Yang, Si Chen, Fei Xia, Di Sun, Deyu Fang, Sidong Xiong, Liping Jin, Jinping Zhang

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Longitudinal Changes of Circulating miRNAs During Bisphosphonate and Teriparatide Treatment in an Animal Model of Postmenopausal Osteoporosis.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2021
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Anfei HuangInstitutes of Biology and Medical Sciences, Soochow University, Suzhou, Jiangsu Province 215123, People's Republic of China.
Yi YangInstitutes of Biology and Medical Sciences, Soochow University, Suzhou, Jiangsu Province 215123, People's Republic of China.
Si ChenInstitutes of Biology and Medical Sciences, Soochow University, Suzhou, Jiangsu Province 215123, People's Republic of China.
Fei XiaInstitutes of Biology and Medical Sciences, Soochow University, Suzhou, Jiangsu Province 215123, People's Republic of China.
Di SunInstitutes of Biology and Medical Sciences, Soochow University, Suzhou, Jiangsu Province 215123, People's Republic of China.
Deyu FangDepartment of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Sidong XiongInstitutes of Biology and Medical Sciences, Soochow University, Suzhou, Jiangsu Province 215123, People's Republic of China.
Liping JinClinical and Translational Research Center, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai 200040, China.
Jinping ZhangInstitutes of Biology and Medical Sciences, Soochow University, Suzhou, Jiangsu Province 215123, People's Republic of China.
Soochow University · CNNorthwestern University · USShanghai First Maternity and Infant Hospital · CN

Funding

Simultaneous Targeting of IRE1a in B Cells and Macrophages for Lupus TherapyR01AR066634 · NIAMS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI FANG, DEYU, ZHANG, KEZHONG · 2014 to 2018
$1.7M
NIAMS NIH HHS R01 AR066634
6 · The paper itself

Abstract

MicroRNAs serve important functions in numerous biological processes. Whether microRNAs also act on dendritic cell (DC) differentiation and function remains unclear. In this study, both conventional DCs (cDCs) and plasmacytoid DCs (pDCs) were increased in miR-34a overexpressing bone marrow chimeric and transgenic (TG) mice. Further experiments showed that miR-34a promoted preDC differentiated into cDCs and pDCs without affecting the proliferation and apoptosis of DCs. Luciferase report assay and Western blot experiments demonstrated that WNT1 is the direct target of miR-34a in DCs. Interestingly, miR-34a overexpressing cDCs also produced a large amount of IL-17a and suppressed T cell activation because of the inhibition of TCF1 expression, thus increasing RORγT expression. Taken together, miR-34a promotes preDC to differentiate into cDCs and pDCs, as well as inhibits the function of cDCs on the activation of CD4+ T cells by producing IL-17a.

Indexed as

AnimalsBlotting, WesternCell DifferentiationDendritic CellsGene Expression RegulationHEK293 CellsHepatocyte Nuclear Factor 1-alphaHumansInterleukin-17Lymphocyte ActivationMice, Inbred C57BLMice, Inbred StrainsMice, KnockoutMice, TransgenicMicroRNAsNuclear Receptor Subfamily 1, Group F, Member 3Hepatocyte Nuclear Factor 1-alphaHnf1a protein, mouseInterleukin-17MicroRNAsMIRN34a microRNA, mouseNuclear Receptor Subfamily 1, Group F, Member 3Wnt1 ProteincDCsdevelopmentIL-17amiR-34aT cell activation

Identifiers

PMID28199987
PMCPMC5370032
OpenAlexW2588090172

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.